Article

Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.

Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Villejuif, France.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.31). 04/2009; 94(4):1310-6. DOI: 10.1210/jc.2008-1747
Source: PubMed

ABSTRACT The purpose of the study was to assess prospectively the impact of recombinant human TSH (rhTSH) administration on positron emission tomography (PET)/computed tomography (CT) imaging in differentiated thyroid cancer patients who, after primary treatment, had a suppressed or stimulated serum thyroglobulin greater than 10 ng/ml and no radioactive iodine uptake consistent with thyroid cancer on a whole body scan.
PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.
A total of 108 lesions were detected in 48 organs in 30 patients. rhTSH-PET was significantly more sensitive than basal PET for the detection of lesions (95 vs. 81%; P = 0.001) and tended to be more sensitive for the detection of involved organs (94 vs. 79%; P = 0.054). However, basal PET and rhTSH-PET did not have significantly different sensitivity for detecting patients with any lesions (49 vs. 54%; P = 0.42). Changes in treatment management plan occurred in 19% of the patients after basal PET. Lesions found only by rhTSH-PET contributed to an altered therapeutic plan in eight patients, among whom only four were true-positive on pathology (6%).
The use of rhTSH for 2-[18F]-fluoro-2-deoxy-D-glucose-PET/CT significantly increased the number of lesions detected, but the numbers of patients in whom any lesion was detected were no different between basal and rhTSH-stimulated PET/CT scans. Treatment changes due to true positive lesions occurred in 6% of cases.

0 Bookmarks
 · 
121 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Differentiated thyroid carcinomas (DTC) originating from thyroid follicular cells are frequent tumors of the thyroid with relatively good prognosis due to improved surgical techniques and follow-up procedures. Poorly differentiated thyroid cancers, that loose iodine uptake ability, in most cases still express TSH receptors (TSHR). Therefore, the aim of this study was to radiolabel a superagonist recombinant human TSH (rhTSH) analogue for imaging poorly differentiated thyroid cancer. Methods: The TSHR superagonist, TR1401, was labeled with 99mTc using an indirect method via succinimidyl-6-hydrazinonicotinate hydrochloride conjugation. In vitro quality controls (QC) included SDS-PAGE, cysteine challenge and cell binding assay on TSHR positive cell lines (JP09 and ML-1). In vivo studies included tumor targeting experiments in athymic nude CD-1 mice xenografted with several different TSHR positive cells (JP09, K1 and ML-1) and TSHR negative cells (JP02) as control. Results: The superagonist rhTSH analogue TR1401 was labeled with high labeling efficiency (>95%) and high specific activity (9250 MBq/mg). The labeled molecule retained its biological activity and structural integrity. In tumor targeting experiments, a focal uptake of radiolabeled TR1401 was observed in TSHR positive cells but not in TSHR negative cells. The same observation was made in a dog with spontaneous intra-glandular thyroid cancer. Conclusions: We were able to efficiently radiolabel the rhTSH superagonist analogue TR1401 with 99mTc with retention of in vitro and in vivo binding capacity to TSHR. The relative role of such novel radiopharmaceutical versus 131I scanning of thyroid cancer will require future histopathological and clinical studies , but it may open new perspectives for pre-surgical staging of thyroid cancer, for diagnosis of radioiodine negative local relapses and/or distant metastases.
    Thyroid: official journal of the American Thyroid Association 05/2014; 24(8). · 2.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the follow-up of differentiated thyroid cancer (DTC) after a successful total-near total thyroidectomy and I-131 ablation therapy, anti-thyroglobulin antibodies (anti-Tg) may be persistently or progressively increased in the patients with an undetectable serum thyroglobulin (Tg) level. In these cases, further investigation was performed to search for recurrence/metastases. The aim of our study was clarifying the role of FDG-PET/CT in detecting recurrence/metastasis in patients with DTC with negative serum Tg and elevated anti-Tg level.
    Annals of Nuclear Medicine 08/2014; 28(10). · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The early detection of recurrent thyroid cancer and focussed surgery are essential for patients' prognosis. Using I-131 whole body scintigraphy is often not sufficient to detect recurrent carcinoma making other imaging methods necessary to identify the tumor. Recent studies showed that positron emission tomography-computed tomography (PET/CT) is able to identify recurrent carcinoma and metastasis at an early stage.
    Der Chirurg 05/2014; 85(6). · 0.52 Impact Factor

Preview

Download
0 Downloads
Available from